EST Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics (BEAM) todayDiscover the Best Stocks and Maximize Your Portfolio: ...

Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...

NASDAQ BEAM opened at $25.59 on Monday. Beam Therapeutics has a 52 week low of $20.84 and a 52 week high of $49.50. The business’s fifty day simple moving average is $26.50 and its 200-day ...

While it may not be enough for some shareholders, we think it is good to see the Beam Therapeutics Inc. (NASDAQ:BEAM) share price up 19% in a single quarter. But over the last three years we've ...

In a move that caught the attention of investors, ARK significantly increased its holdings in Beam Therapeutics Inc (NASDAQ:BEAM), purchasing a total of 170,778 shares valued at approximately $5. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...